Literature DB >> 15842039

Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field.

Lan Zhou1, Alvin H Schmaier.   

Abstract

Platelet function testing consisting of platelet aggregation and secretion often is requested in the clinical evaluation of patients with bleeding problems. At present, there are no uniform clinical laboratory standards for the performance or interpretation of these studies. The present report describes one laboratory's methods and interpretations of platelet aggregation and secretion studies of platelet-rich plasma using each of the common platelet agonists. Diagnostic categories for the evaluation of the platelet function testing are presented. The diagnostic categories then are applied to the evaluation of 61 patients referred to our medical center for these studies. The aims of this report are to present clinical platelet aggregation and secretion studies and to provide a working schema to evaluate these results. Our intent is to stimulate interest in the development of professional guidelines for platelet function testing in the clinical laboratory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15842039     DOI: 10.1309/y9ec-63rw-3xg1-v313

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  38 in total

1.  In vitro impact of laser irradiation on platelet aggregation.

Authors:  Eman A Shakir; Nabaa A Rasheed Naji
Journal:  Lasers Med Sci       Date:  2018-05-07       Impact factor: 3.161

2.  Evaluating platelet aggregation dynamics from laser speckle fluctuations.

Authors:  Zeinab Hajjarian; Diane M Tshikudi; Seemantini K Nadkarni
Journal:  Biomed Opt Express       Date:  2017-06-30       Impact factor: 3.732

3.  Women with red hair report a slightly increased rate of bruising but have normal coagulation tests.

Authors:  Edwin B Liem; Sandra C Hollensead; Teresa V Joiner; Daniel I Sessler
Journal:  Anesth Analg       Date:  2006-01       Impact factor: 5.108

4.  State of the art in platelet function testing.

Authors:  Beate E Kehrel; Martin F Brodde
Journal:  Transfus Med Hemother       Date:  2013-03-18       Impact factor: 3.747

5.  Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF.

Authors:  Vyala Hanumanthareddy Chaithra; Shancy Petsel Jacob; Chikkamenahalli Lakshminarayana Lakshmikanth; Mosale Seetharam Sumanth; Kandahalli Venkataranganayaka Abhilasha; Chu-Huang Chen; Anita Thyagarajan; Ravi P Sahu; Jeffery Bryant Travers; Thomas M McIntyre; Kempaiah Kemparaju; Gopal Kedihithlu Marathe
Journal:  J Lipid Res       Date:  2018-08-23       Impact factor: 5.922

6.  Hirudins of the Asian medicinal leech, Hirudinaria manillensis: same same, but different.

Authors:  Phil Lukas; Robert Wolf; Bernhard H Rauch; Jan-Peter Hildebrandt; Christian Müller
Journal:  Parasitol Res       Date:  2019-06-11       Impact factor: 2.289

7.  The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations.

Authors:  Deborah L Higgins; Mike P Ero; Michelle Loeb; Kathryn Kersey; Alan Hopkins; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-08       Impact factor: 3.000

Review 8.  Pulmonary Fibrosis in Hermansky-Pudlak Syndrome.

Authors:  Glenn W Vicary; Yeidyly Vergne; Alberto Santiago-Cornier; Lisa R Young; Jesse Roman
Journal:  Ann Am Thorac Soc       Date:  2016-10

9.  Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets.

Authors:  Maria Dona; Gabrielle Fredman; Jan M Schwab; Nan Chiang; Makoto Arita; Ahmad Goodarzi; Guiying Cheng; Ulrich H von Andrian; Charles N Serhan
Journal:  Blood       Date:  2008-05-14       Impact factor: 22.113

10.  Thrombin-targeted liposomes establish a sustained localized anticlotting barrier against acute thrombosis.

Authors:  Rohun U Palekar; Jacob W Myerson; Paul H Schlesinger; J Evan Sadler; Hua Pan; Samuel A Wickline
Journal:  Mol Pharm       Date:  2013-10-10       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.